Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-004789-14 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label, multi-center,12 week extension study designed to evaluate the longer term safety, tolerability and effectiveness of lurasidone, flexibly dosed, adjunctive to lithium or divalproex for the treatment of subjects with bipolar I disorder, who have either completed the core study D1050296 or experienced a protocol defined recurrence of a mood event in the double-blind phase of the core study D1050296
To evaluate the longer term safety of lurasidone (20, 40, 60 or 80 mg/day) in subjects with bipolar I disorder.
Subjects will be initially treated with open-label lurasidone 40 mg/day (Day 1).
Dose adjustment of study drug (20, 40, 60 or 80 mg /day) should occur at the regularly scheduled visits and in increments/decrements of 1 dose level.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lurasidone | Experimental | Lurasidone 20, 40, 60,80 mg flexible dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lurasidone | Drug | Lurasidone 20-80 mg taken orally once daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-emergent Adverse Events and Treatment-emergent Adverse Events Leading to Discontinuation and Serious Adverse Events | Number of subjects with treatment emergent AEs, SAEs, and TEAEs leading to discontinuation | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to Week 12 (LOCF) in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR16) Total Score | The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lurasidone Medical Director, MD | Sumitomo Pharma America, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Harmonex Neuroscience Research | Dothan | Alabama | 36303 | United States | ||
| Behavioral Research Specialists, LLC |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Lurasidone | Lurasidone 20, 40, 60,80 mg flexible dose Lurasidone: Lurasidone 20-80 mg taken orally once daily |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| baseline, 12 weeks (LOCF) |
| Change From Baseline to Week 12 (LOCF) in the Positive and Negative Syndrome Scale Positive Subscale (PANSS P) Score | The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity. | baseline, 12 weeks (LOCF) |
| Change From Baseline to Week 12 (LOCF) in the YMRS Total Score -Mania as Assessed by Young Mania Rating Scale (YMRS) | Movement disorders as assessed by Young Mania Rating Scale (YMRS) The YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of mania. | Baseline, 12 weeks (LOCF) |
| Change From Baseline to Week 12 (LOCF) in the MADRS Total Score- Depression as Assessed by Montgomery-Asberg Depression Rating Scale (MADRS) | Depression as assessed by Montgomery-Asberg Depression Rating Scale (MADRS) -The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depression. | baseline ,Week 12 (LOCF) |
| Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Overall Score- Severity of Illness as Assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) | Severity of illness as assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) -The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. | baseline, week 12 (LOCF) |
| Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Mania Score | The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7= Among the most extremely ill patients. A higher score is associated with greater illness severity | baseline, week 12 (LOCF) |
| Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Depression Scale | The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and range from 1=normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with greater illness severity. | baseline, week 12 (LOCF) |
| Change From Baseline to Week 12 (LOCF) in the SDS Total Score | The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing. | baseline, week 12 (LOCF) |
| Glendale |
| California |
| 91206 |
| United States |
| AXIS Clinical Trials | Los Angeles | California | 90036 | United States |
| Excell Research, Inc | Oceanside | California | 92056 | United States |
| Stanford University School of Medicine Research Program VA Palo Alto Health Care System | Palo Alto | California | 93404 | United States |
| SF-Care, Inc. | San Francisco | California | 94117 | United States |
| Neuropsychiatric Research Center of Orange County | Santa Ana | California | 92701 | United States |
| Stanford University School of Medicine | Stanford | California | 93405 | United States |
| Florida Clinical Research LLC | Bradenton | Florida | 34201 | United States |
| Clinical Neuroscience Solutions Inc. | Jacksonville | Florida | 32216 | United States |
| Galiz Research | Miami Springs | Florida | 33166 | United States |
| Clinical Neuroscience Solutions | Orlando | Florida | 32806 | United States |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30308 | United States |
| Clinco | Terre Haute | Indiana | 47802 | United States |
| Activ Med Practices & Research | Haverhill | Massachusetts | 08130 | United States |
| Psych Care Consultants Research | St Louis | Missouri | 63128 | United States |
| Finger Lakes Clinical Research | Rochester | New York | 14618 | United States |
| Charak Clincial Research Center | Garlield Heights | Ohio | 44125 | United States |
| Cutting Edge Research Group | Oklahoma City | Oklahoma | 73116 | United States |
| Suburban Research Associates | Media | Pennsylvania | 19063 | United States |
| Lincoln Research | Lincoln | Rhode Island | 02865 | United States |
| Carolina Clinical Trials | Charleston | South Carolina | 29407 | United States |
| Clinical Neuroscience Solutions Inc. | Memphis | Tennessee | 38119 | United States |
| Psychoneuroendocrinology Research Group, Dept of Psychiatry, UT Southwestern Medical Center | Dallas | Texas | 75235 | United States |
| R/D Clinical Research, Inc. | Lake Jackson | Texas | 77566 | United States |
| Clinica Privada de Salud Mental Santa Teresa de Avila | Buenos Aires | 1900 | Argentina |
| Novain Neurociencias Group | Buenos Aires | C1117ABH | Argentina |
| Instituto Nacional de Psicopatología (INAPSI) | Buenos Aires | C1405BOA | Argentina |
| Fundacion para el estudio y tratamiento de las enfermedades mentales (FETEM) | Buenos Aires | C1425AHQ | Argentina |
| Instituto DAMIC SRL | Córdoba | 5003 | Argentina |
| Centro de Investigacion y Asistencia en Psiquiatria (CIAP) | Rosario | 2000 | Argentina |
| Center for Mental Health | Rousse | 7003 | Bulgaria |
| Multiprofiled Hospital for Active Treatment "Alexandrovska" | Sofia | 1431 | Bulgaria |
| Military Medical Academy | Sofia | 1606 | Bulgaria |
| Hospital El Pino | Santiago | 8053095 | Chile |
| Clinica Pedro Montt | Santiago | 8330838 | Chile |
| Saint Anne, s.r.o., Psychiatricke oddeleni | Brno - Mesto | 602 00 | Czechia |
| Psychiatricka ambulance | Havířov | 73601 | Czechia |
| Psychiatricka lecebna U Honzicka | Písek | 397 01 | Czechia |
| Clintrial s.r.o. | Prague | 100 00 | Czechia |
| Psychiatricka ambulance | Prague | 106 00 | Czechia |
| Psychiatricka ambulance | Prague | 149 00 | Czechia |
| Psychiatricka ambulance Prosek | Prague | 190 00 | Czechia |
| Telemens, s.r.o. | Přerov | 750 01 | Czechia |
| CHS La Chartreuse - Pôle 6 | Dijon | 21033 | France |
| Centre Hospitalier Spécialisé du Jura - Centre Médico Psychiatrique | Dole | 39100 | France |
| Centre Hospitalier Régional Universitaire | Nîmes | 30900 | France |
| Kutvolgyi Klinikai Tomb SOTE IIIsz Belgyogyaszati Klinika | Budapest | 1125 | Hungary |
| Nyiro Gyula Korhaz, I. Pszichiatria | Budapest | 1135 | Hungary |
| Nyiro Gyula Korhaz, II. Pszichiatria | Budapest | 1135 | Hungary |
| Nyiro Gyula Korhaz | Budapest | 1135 | Hungary |
| Goryokai Medical Corporation | Sapporo | Hokkaido | 002-8029 | Japan |
| Asakayama General Hospital | Sakai | Osaka | Japan |
| Yuge Hospital | Kumamoto | 861-8002 | Japan |
| Nishigahara Hospital | Tokyo | 114-0024 | Japan |
| Kawada Hospital | Toyama | 933-0917 | Japan |
| NZOZ Syntonia | Gdynia | 81-361 | Poland |
| NZOZ BioMed | Kielce | 25-411 | Poland |
| NZOZ Prywatna Klinika Psychiatryczna Inventiva | Tuszyn | 95-080 | Poland |
| State Healthcare and Forensic Psychiatric Expertise Institution | Izhevsk | 426054 | Russia |
| Saint Petersburg State Healthcare Institution "City psycho-neurology Dispanser #7" | Saint Petersburg | 190005 | Russia |
| St Petersburg State Government Healthcare Institution | Saint Petersburg | 190121 | Russia |
| St. Petersburg State Healthcare Institution "City Clinical Hospital #4" | Saint Petersburg | 191119 | Russia |
| Mental Health Research Institute of Siberian Branch of RAMS | Tomsk | 634014 | Russia |
| Nizhny Novgorod Regional State Institution of Healthcare | Veliky Novgorod | 603155 | Russia |
| Clinical Hospital Centre Dragisa Misovic | Belgrade | 11000 | Serbia |
| Clinical Centre Kragujevac, Psychiatric Hospital | Kragujevac | 34000 | Serbia |
| Clinic for Mental Health Protection, Clinical Centre Nis | Niš | 18000 | Serbia |
| Specialized Hospital for Psychiatric Diseased "Sveti Vracevi" | Novi Kneževac | 23330 | Serbia |
| Psychiatricke oddelenie, Vseobecna nemocnica Rimavska Sobota NaP n.o. | Rimavská Sobota | 97912 | Slovakia |
| Psychiatricka ambulancia | Zlaté Moravce | 95301 | Slovakia |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Lurasidone | Lurasidone 20, 40, 60,80 mg flexible dose Lurasidone: Lurasidone 20-80 mg taken orally once daily |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| |||||||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Treatment-emergent Adverse Events and Treatment-emergent Adverse Events Leading to Discontinuation and Serious Adverse Events | Number of subjects with treatment emergent AEs, SAEs, and TEAEs leading to discontinuation | Posted | Number | participants | 12 weeks |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR16) Total Score | The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms. | only 351 of the 377 subjects had the QIDS-SR16 assessment at week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | baseline, 12 weeks (LOCF) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the Positive and Negative Syndrome Scale Positive Subscale (PANSS P) Score | The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity. | only 359 of the 377 subjects had the PANSS-P assessment at week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | baseline, 12 weeks (LOCF) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the YMRS Total Score -Mania as Assessed by Young Mania Rating Scale (YMRS) | Movement disorders as assessed by Young Mania Rating Scale (YMRS) The YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of mania. | only 375 of the 377 subjects had the YMRD assessment at week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | Baseline, 12 weeks (LOCF) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the MADRS Total Score- Depression as Assessed by Montgomery-Asberg Depression Rating Scale (MADRS) | Depression as assessed by Montgomery-Asberg Depression Rating Scale (MADRS) -The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depression. | Only 375 of the 377 subjects had the MADRS assessment at week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | baseline ,Week 12 (LOCF) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Overall Score- Severity of Illness as Assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) | Severity of illness as assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) -The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. | only 375 of the 377 subjects had the CGI-BP-S overall assessment at week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | baseline, week 12 (LOCF) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Mania Score | The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7= Among the most extremely ill patients. A higher score is associated with greater illness severity | Only 375 of the 377 subjects had the CGI-BP-S mania assessment at week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | baseline, week 12 (LOCF) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Depression Scale | The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and range from 1=normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with greater illness severity. | only 375 of the 377 subjects had the CGI-BP-S depression assessment at Week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | baseline, week 12 (LOCF) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 12 (LOCF) in the SDS Total Score | The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing. | only 297 of the 377 subjects had the SDS total score at week 12 (LOCF) | Posted | Mean | Standard Deviation | units on a scale | baseline, week 12 (LOCF) |
|
|
12 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Lurasidone | Lurasidone 20, 40, 60,80 mg flexible dose Lurasidone: Lurasidone 20-80 mg taken orally once daily | 14 | 377 | 51 | 377 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| anaemia megaloblastic | Blood and lymphatic system disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| craniocerebral injury | Injury, poisoning and procedural complications | MedDRA 15.0 | Non-systematic Assessment |
| |
| femur fracture | Injury, poisoning and procedural complications | MedDRA 15.0 | Non-systematic Assessment |
| |
| intentional overdose | Injury, poisoning and procedural complications | MedDRA 15.0 | Non-systematic Assessment |
| |
| basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 15.0 | Non-systematic Assessment |
| |
| depression | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| mania | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| bipolar disorder | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| emotional distress | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| panic attack | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| persecutory delusion | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| accelerated hyertension | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| nausea | Gastrointestinal disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| nasopharyngitis | Infections and infestations | MedDRA 15.0 | Non-systematic Assessment |
| |
| headache | Nervous system disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| akathisia | Nervous system disorders | MedDRA 15.0 | Non-systematic Assessment |
| |
| insomnia | Psychiatric disorders | MedDRA 15.0 | Non-systematic Assessment |
|
In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| CNS Medical Director | Sunovion Pharmaceuticals Inc. | 1-866-503-6351 | clinicaltrialdisclosure@sunvion.com |
| ID | Term |
|---|---|
| D001714 | Bipolar Disorder |
| ID | Term |
|---|---|
| D000068105 | Bipolar and Related Disorders |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069056 | Lurasidone Hydrochloride |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D054833 | Isoindoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Argentina |
|
| Hungary |
|
| United States |
|
| Japan |
|
| Poland |
|
| Slovakia |
|
| Bulgaria |
|
| France |
|
| Chile |
|
| Serbia |
|
| Title | Measurements |
|---|---|
|
| at least 1 treatment emergent SAE related to drug |
|
| at least 1 TEAE leading to discontinuation |
|
|
|
|
|
|
|
|
|